Jan 21, 2025, 09:58
Kristina Jankovic: Intratumoral Pembrolizumab and mRNA-2752 for High-Risk DCIS
Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, posted the following on X:
“Intratumoral pembrolizumab and mRNA-2752 for high-risk DCIS: Phase 1 nonrandomized trial
- 80% response rate
- No major systemic toxicities
- Complete tumor resolution in some cases, possibly reducing surgery
Ongoing studies are needed.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 21, 2025, 09:59
Jan 21, 2025, 09:58
Jan 21, 2025, 09:58
Jan 21, 2025, 09:39
Jan 21, 2025, 09:27
Jan 21, 2025, 09:04